Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Truman123 who wrote (54858)	7/17/2000 11:06:19 AM
From: Theo	Read Replies (1) \| Respond to of 150070

"Added more CLYC today." So have I, and have been every day for a week straight...:) In that article in the Sarasota Herald-Tribune posted on RB, I think some folks might be missing the point of what sets DNAprint Genomics apart from the other biotechs involved in genomics et al: "Investors could reap big profits as drug companies mine human genome studies and race to produce a new family of drugs to combat ancient illnesses...Though experts say years could pass before a new crop of disease-fighting treatments lands on shelves, a Southwest Florida company is aiming to re-examine the potential for existing drugs... "There's a tremendous profit potential in looking at FDA-approved drugs because for some people (who fall into a certain genotype pattern) they can be harmful," chief scientific officer Tony Frudakis said from DNAprint Genomics' laboratory, 1748 Independence Blvd...That DNAprint looks at existing drugs' reactiveness within the population sets it apart from other young biotechs that concentrate on pioneering new treatments... Theo;-)